318 related articles for article (PubMed ID: 10861231)
21. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
22. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
Medicus RG; Götze O; Müller-Eberhard HJ
J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
24. Preferential formation of C3b-IgG complexes in vitro and in vivo from nascent C3b and naturally occurring anti-band 3 antibodies.
Lutz HU; Stammler P; Fasler S
J Biol Chem; 1993 Aug; 268(23):17418-26. PubMed ID: 8349625
[TBL] [Abstract][Full Text] [Related]
25. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
[TBL] [Abstract][Full Text] [Related]
26. Regulation of C5 convertase activity by properdin, factors B and H.
Weiler JM
Immunol Res; 1989; 8(4):305-15. PubMed ID: 2531781
[No Abstract] [Full Text] [Related]
27. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
Gadd KJ; Reid KB
Biochem J; 1981 May; 195(2):471-80. PubMed ID: 7316962
[TBL] [Abstract][Full Text] [Related]
28. The Role of Properdin in Killing of Non-Pathogenic
Martinez APG; Abreu PAE; de Arruda Vasconcellos S; Ho PL; Ferreira VP; Saggu G; Barbosa AS; Isaac L
Front Immunol; 2020; 11():572562. PubMed ID: 33240263
[TBL] [Abstract][Full Text] [Related]
29. The C3/C5 convertase of the alternative pathway of complement: stabilization and restriction of control by lanthanide ions.
Fishelson Z; Müller-Eberhard HJ
Mol Immunol; 1983 Mar; 20(3):309-15. PubMed ID: 6553181
[TBL] [Abstract][Full Text] [Related]
30. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
Schreiber RD; Medicus RG; Gïtze O; Müller-Eberhard HJ
J Exp Med; 1975 Sep; 142(3):760-72. PubMed ID: 1165475
[TBL] [Abstract][Full Text] [Related]
31. Effect of complement-protein-C3b density on the binding of complement factor H to surface-bound C3b.
Koistinen V
Biochem J; 1991 Nov; 280 ( Pt 1)(Pt 1):255-9. PubMed ID: 1835839
[TBL] [Abstract][Full Text] [Related]
32. C3b generation is affected by the structure of the O-antigen polysaccharide in lipopolysaccharide from salmonellae.
Jimenez-Lucho VE; Joiner KA; Foulds J; Frank MM; Leive L
J Immunol; 1987 Aug; 139(4):1253-9. PubMed ID: 2440949
[TBL] [Abstract][Full Text] [Related]
33. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
Sahu A; Isaacs SN; Soulika AM; Lambris JD
J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
[TBL] [Abstract][Full Text] [Related]
34. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
[TBL] [Abstract][Full Text] [Related]
35. Modulation of the formation of the human amplification C3 convertase of complement by polycations.
Maillet F; Kazatchkine MD
Immunology; 1983 Sep; 50(1):27-33. PubMed ID: 6554235
[TBL] [Abstract][Full Text] [Related]
36. Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies.
Ramadass M; Ghebrehiwet B; Smith RJ; Kew RR
J Immunol; 2014 Feb; 192(3):1220-30. PubMed ID: 24367026
[TBL] [Abstract][Full Text] [Related]
37. Expression and characterisation of the thrombospondin type I repeats of human properdin.
Perdikoulis MV; Kishore U; Reid KB
Biochim Biophys Acta; 2001 Aug; 1548(2):265-77. PubMed ID: 11513971
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2-encoded ORF8 protein possesses complement inhibitory properties.
Kumar J; Dhyani S; Kumar P; Sharma NR; Ganguly S
J Biol Chem; 2023 Mar; 299(3):102930. PubMed ID: 36682494
[TBL] [Abstract][Full Text] [Related]
39. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
Daha MR; Kok DJ; Van Es LA
Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
[TBL] [Abstract][Full Text] [Related]
40. Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b.
Maillet F; Kazatchkine MD; Glotz D; Fischer E; Rowe M
Mol Immunol; 1983 Dec; 20(12):1401-4. PubMed ID: 6558419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
